Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2022
Context: The filing serves as a Regulation FD disclosure to distribute an investor presentation to institutional investors and analysts. The presentation replaces all prior investor presentations and is available on the company website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for an attached investor presentation (Exhibit 99.1) rather than a financial statement itself.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 8-K. The primary change noted is the replacement of all prior investor presentations with the new January 2022 presentation.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing explicitly states that the information in the investor presentation may be amended or updated at any time.
- Liability Disclaimer: The information provided in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Availability: The company reserves the right to discontinue the availability of the presentation on its website at any time.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation dated January 2022) for specific financial data and strategic outlook.
- Verify the current availability of the presentation on the company website (www.aquestive.com).
- Confirm that no subsequent 8-K filings have amended or superseded the January 2022 presentation.